Deciphera Pharmaceuticals (NASDAQ:DCPH) Sets New 1-Year High at $17.74

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPHGet Rating) hit a new 52-week high during mid-day trading on Thursday . The company traded as high as $17.74 and last traded at $17.74, with a volume of 328 shares traded. The stock had previously closed at $17.50.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. SVB Leerink boosted their price target on shares of Deciphera Pharmaceuticals from $15.00 to $21.00 and gave the stock an “outperform” rating in a research report on Friday, August 5th. Cowen assumed coverage on shares of Deciphera Pharmaceuticals in a research report on Monday, August 29th. They issued an “outperform” rating and a $25.00 price target on the stock. JMP Securities upgraded shares of Deciphera Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $23.00 price target on the stock in a research report on Friday, August 5th. Cowen assumed coverage on shares of Deciphera Pharmaceuticals in a research report on Monday, August 29th. They issued an “outperform” rating and a $25.00 price target on the stock. Finally, HC Wainwright boosted their price target on shares of Deciphera Pharmaceuticals from $15.00 to $20.00 and gave the stock a “buy” rating in a research report on Friday, August 5th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, Deciphera Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $16.30.

Deciphera Pharmaceuticals Stock Performance

The firm’s 50 day moving average price is $14.84 and its two-hundred day moving average price is $11.84. The company has a market cap of $1.21 billion, a P/E ratio of -4.22 and a beta of 1.00.

Deciphera Pharmaceuticals (NASDAQ:DCPHGet Rating) last released its quarterly earnings data on Thursday, August 4th. The company reported ($0.60) earnings per share for the quarter, beating the consensus estimate of ($0.65) by $0.05. The company had revenue of $32.49 million during the quarter, compared to analyst estimates of $30.11 million. Deciphera Pharmaceuticals had a negative net margin of 231.99% and a negative return on equity of 74.37%. Deciphera Pharmaceuticals’s revenue for the quarter was up 37.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.21) EPS. As a group, analysts forecast that Deciphera Pharmaceuticals, Inc. will post -2.5 EPS for the current fiscal year.

Institutional Trading of Deciphera Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. US Bancorp DE increased its stake in Deciphera Pharmaceuticals by 100.6% during the 2nd quarter. US Bancorp DE now owns 4,052 shares of the company’s stock valued at $53,000 after purchasing an additional 2,032 shares in the last quarter. Lazard Asset Management LLC bought a new stake in Deciphera Pharmaceuticals during the 1st quarter valued at $57,000. Amalgamated Bank bought a new stake in Deciphera Pharmaceuticals during the 1st quarter valued at $57,000. Denali Advisors LLC increased its stake in Deciphera Pharmaceuticals by 33.9% during the 1st quarter. Denali Advisors LLC now owns 7,900 shares of the company’s stock valued at $73,000 after purchasing an additional 2,000 shares in the last quarter. Finally, TD Asset Management Inc. bought a new stake in Deciphera Pharmaceuticals during the 2nd quarter valued at $134,000. Institutional investors own 72.29% of the company’s stock.

About Deciphera Pharmaceuticals

(Get Rating)

Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.

Featured Articles

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.